| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.084 | 0.03 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.069 | 0.03 |
| mRNA | PF-4708671 | GDSC1000 | pan-cancer | AAC | -0.073 | 0.03 |
| mRNA | isoliquiritigenin | CTRPv2 | pan-cancer | AAC | 0.14 | 0.03 |
| mRNA | Pazopanib | GDSC1000 | pan-cancer | AAC | 0.07 | 0.03 |
| mRNA | pluripotin | CTRPv2 | pan-cancer | AAC | -0.075 | 0.04 |
| mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | -0.063 | 0.04 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | 0.067 | 0.04 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.092 | 0.04 |
| mRNA | ATRA | GDSC1000 | pan-cancer | AAC | 0.066 | 0.05 |